Migraine Is a Neuroinflammatory Condition, Not a Vascular One
research · Multiple clinical trials and mechanistic studies (CGRP antagonists, gepants, animal models) (2026)
The vascular theory of migraine—that it’s caused by blood vessel dilation—has been largely debunked. Current evidence shows migraine is a neuroinflammatory condition driven by activation of the trigeminovascular system and release of CGRP (calcitonin gene-related peptide) and other inflammatory mediators. This shift has opened the door to targeted therapies.
Core Concepts
The Problem
The outdated vascular model led to treatments that often failed and left patients misunderstood.
The Claim
Migraine arises from neuroinflammation in the brain and meninges, not from blood vessel dilation alone.
Key Evidence
- •CGRP antagonists (gepants) and monoclonal antibodies are effective in treating and preventing migraine, validating the neuroinflammatory mechanism.
- •Imaging studies show inflammatory changes in the meninges during migraine attacks.
- •The lack of efficacy of traditional vasoconstrictors for many patients supports the need for a new model.
Practical Implication
Patients now have more effective, targeted options that directly address the underlying biology rather than just constricting blood vessels.
Nuance & Limits
Some medical schools still teach the vascular model, so patients may need to seek out specialists aware of the updated science. Also, not all migraines are purely neuroinflammatory; there are subtypes, and triggers vary.
Source Material
Citation Density
Field-wide consensus supported by thousands of studies and clinical trials in the past decade.
Gaps
- ⚠ More research needed on subtypes of migraine that may not respond to CGRP-targeted therapies.
- ⚠ Long-term outcomes and cost-effectiveness of newer treatments still being evaluated.
Discuss Further
Open this concept in an AI assistant for deeper discussion, critique, or exploration.